What did the FDA find wrong with Omron (Dalian) Co., Ltd. (Plant 1)?

The FDA issued a warning letter citing regulatory violations related to their products or manufacturing practices.

Are Omron (Dalian) Co., Ltd. (Plant 1) products safe to use?

Based on the FDA's findings, consumers should exercise caution. The company was found to have regulatory issues that may affect product safety.

What should I do if I've used Omron (Dalian) Co., Ltd. (Plant 1) products?

If you have used products from Omron (Dalian) Co., Ltd. (Plant 1) and experience any adverse effects, contact your healthcare provider immediately. You can also report adverse events to the FDA's MedWatch program.

Omron (Dalian) Co., Ltd. (Plant 1) FDA Warning (2017)

Name: Omron (Dalian) Co., Ltd. (Plant 1) FDA Warning (2017)
Creator: Supplement Safety Data Team
Published: 2026-03-27T01:44:18.369583

Compiled by the Supplement Safety Data Team | Sourced from Official FDA Records on June 05, 2017

MODERATE SEVERITY 2017

Disclaimer: This report is an analysis of a public FDA warning letter. It is not medical advice. If you have consumed these products and feel unwell, contact a healthcare professional immediately.

Executive Summary

The FDA issued a warning letter to Omron (Dalian) Co., Ltd. (Plant 1) on June 05, 2017 citing regulatory violations. The letter was issued by the FDA.

Regulatory Violations

Detailed Analysis

False Claims and Regulatory Violations

The FDA identified regulatory violations in Omron (Dalian) Co., Ltd. (Plant 1)'s operations or product claims.

Potential Health Risks

Ronald L. Swann, M.S.Acting Director Division of InternationalCompliance OperationsOffice of ComplianceCenter for Devices and Radiological Health

U.S. AgentRenee ThornboroughOMRON HEALTHCARE, INC.1925 W. Field Court, Suite 100Lake Forest, IL 60045

Regulatory Context

The Food and Drug Administration has completed an evaluation of your firm's corrective actions in response to our Warning Letter (CMS 273116, dated February 14, 2012). Based on our evaluation, it appears that you have addressed the violations contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.

This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.

Key Entities Identified

Omron (Dalian) Co. Ltd. (Plant 1) FDA Warning Letter

Frequently Asked Questions

What did the FDA find wrong with Omron (Dalian) Co., Ltd. (Plant 1)?: The FDA issued a warning letter citing regulatory violations related to their products or manufacturing practices.
Are Omron (Dalian) Co., Ltd. (Plant 1) products safe to use?: Based on the FDA's findings, consumers should exercise caution. The company was found to have regulatory issues that may affect product safety.
What should I do if I've used Omron (Dalian) Co., Ltd. (Plant 1) products?: If you have used products from Omron (Dalian) Co., Ltd. (Plant 1) and experience any adverse effects, contact your healthcare provider immediately. You can also report adverse events to the FDA's MedWatch program.

Source Document

This report is based on an official FDA warning letter. The original document is a public record.

View Original FDA Warning Letter

Medical Disclaimer: This report is an analysis of public FDA warning letters. It is not medical advice. If you have consumed these products and feel unwell, contact a healthcare professional immediately. You can report adverse events to the FDA MedWatch program.